The India liver cancer therapeutics market size reached USD 123.75 Million in 2024. Looking forward, IMARC Group expects the market to reach USD 337.40 Million by 2033, exhibiting a growth rate (CAGR) of 10.85% during 2025-2033. The market is driven by rising liver cancer prevalence, increasing alcohol consumption, growing hepatitis infections, advancements in targeted therapies, expanding healthcare infrastructure, increasing awareness programs, and supportive government initiatives.
Report Attribute
|
Key Statistics
|
---|---|
Base Year
|
2024 |
Forecast Years
|
2025-2033
|
Historical Years
|
2019-2024
|
Market Size in 2024 | USD 123.75 Million |
Market Forecast in 2033 | USD 337.40 Million |
Market Growth Rate (2025-2033) | 10.85% |
Advancements in Targeted Therapies and Immunotherapy
The India liver cancer therapeutics market outlook is witnessing significant advancements in targeted therapies and immunotherapy, offering more effective treatment options with fewer side effects. In addition to this, the treatment success of standard chemotherapy remains limited because hepatocellular carcinoma shows resistance to therapy. Moreover, the medical community has achieved better survival rates by introducing the molecular-targeted drugs sorafenib and lenvatinib. Besides this, the popularity of immunotherapies is increasing because immune checkpoint inhibitors such as nivolumab and pembrolizumab enhance the natural defense systems' reaction to cancer cells. For example, in April 2024, India’s first indigenous CAR-T cell therapy, NexCAR19, developed by IIT Bombay, Tata Memorial Centre, and ImmunoACT, marked a significant advancement in affordable gene therapy, further strengthening the country’s position in cancer treatment innovation. Furthermore, the approval process for new therapeutic approaches along with rising clinical studies continues to develop available treatment options. Medical research centers and pharmaceutical enterprises also use their resources to develop integrated immunotherapy and targeted drug programs that enhance the treatment results. As a result, patients have access to these treatments, driven by the rising demand for precise liver cancer treatment options, which is boosting the India liver cancer therapeutics market share.
Growing Adoption of Minimally Invasive and Locoregional Therapies
The India liver cancer therapeutics market is observing an increasing trend for minimally invasive (MI) and locoregional treatments because these procedures show success in treating early-stage cancers and providing palliative care. Doctors across India are widely adopting Transarterial Chemoembolization (TACE), Transarterial Radioembolization (TARE), and Radiofrequency Ablation (RFA) as targeted tumor treatments as they demonstrate minimal impact on healthy tissues. For instance, in March 2025, Terumo India launched the Occlusafe balloon occlusion catheter, enhancing precision in TACE procedures for liver cancer. This innovation aligns with India's growing adoption of MI treatments, improving outcomes and reinforcing the shift toward advanced interventional oncology solutions. The procedures benefit patients whose condition makes them ineligible for surgical resection or liver transplantation. Concurrently, the expanding number of dedicated cancer treatment facilities and enhanced imaging systems along with doctors' growing expertise in interventional oncology practices has led to wider use of these therapy methods. Additionally, locoregional treatments are gaining popularity in India’s cost-sensitive healthcare environment as they offer affordability and reduced hospitalization periods. Apart from this, the increased availability and awareness of these procedures establish them as fundamental methods in liver cancer management to enhance survival outcomes for patients, thereby driving the India liver cancer therapeutics market growth.
IMARC Group provides an analysis of the key trends in each segment of the market, along with forecasts at the region level for 2025-2033. Our report has categorized the market based on cancer type, therapy, route of administration and distribution channel.
Cancer Type Insights:
The report has provided a detailed breakup and analysis of the market based on the cancer type. This includes hepatocellular carcinoma, cholangiocarcinoma, hepatoblastoma, angiosarcoma, and liver metastasis.
Therapy Insights:
A detailed breakup and analysis of the market based on the therapy have also been provided in the report. This includes targeted therapy, chemotherapy and radiation therapy, immunotherapy, and others.
Route of Administration Insights:
The report has provided a detailed breakup and analysis of the market based on the route of administration. This includes oral, intravenous, and others.
Distribution Channel Insights:
A detailed breakup and analysis of the market based on the distribution channel have also been provided in the report. This includes hospital pharmacies, retail pharmacies, and online pharmacies.
Regional Insights:
The report has also provided a comprehensive analysis of all the major regional markets, which include North, South, East and West India.
The market research report has also provided a comprehensive analysis of the competitive landscape. Competitive analysis such as market structure, key player positioning, top winning strategies, competitive dashboard, and company evaluation quadrant has been covered in the report. Also, detailed profiles of all major companies have been provided.
Report Features | Details |
---|---|
Base Year of the Analysis | 2024 |
Historical Period | 2019-2024 |
Forecast Period | 2025-2033 |
Units | Million USD |
Scope of the Report |
Exploration of Historical Trends and Market Outlook, Industry Catalysts and Challenges, Segment-Wise Historical and Future Market Assessment:
|
Cancer Types Covered | Hepatocellular Carcinoma, Cholangiocarcinoma, Hepatoblastoma, Angiosarcoma, Liver Metastasis |
Therapies Covered | Targeted Therapy, Chemotherapy and Radiation Therapy, Immunotherapy, Others |
Route of Administrations Covered | Oral, Intravenous, Others |
Distribution Channels Covered | Hospital Pharmacies, Retail Pharmacies, Online Pharmacies |
Regions Covered | North India, South India, East India, West India |
Customization Scope | 10% Free Customization |
Post-Sale Analyst Support | 10-12 Weeks |
Delivery Format | PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request) |